AstraZeneca Asks Fed. Circ. To Reopen Nexium Patent Suit

Law360, New York (September 5, 2013, 8:06 PM EDT) -- AstraZeneca AB on Tuesday asked the Federal Circuit to revive its suit against Hanmi Pharmaceutical Co. Ltd., arguing a lower court had wrongly found that the South Korean drugmaker’s copycat version of the acid reflux medication Nexium does not violate AstraZeneca's patents.

In its brief, AstraZeneca argues that U.S. District Judge Joel Pisano wrongly interpreted the definition of “alkaline salt” to find that the active ingredient in Hanmi’s planned product didn't fall under the alkaline salt category. Nexium’s active ingredient is an alkaline magnesium salt of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.